ITCI: Kapitalisasi pasar intracellulartherapies.com

The historical price chart for Intra-Cellular Therapies (ITCI) reflects the dynamics of an asset whose R&D potential is currently peaking as it prepares to expand the application of Caplyta for depression. Market capitalization stands at 13.99, while the business relies on stable, non-cyclical demand within the psychiatry sector. Strong positioning is secured by rigorous patent protection and physician trust, which effectively curbs the expansion of new market entrants.

Intra-Cellular Therapies Inc. - Kapitalisasi pasar ITCI (periode 04.07.2022 - 13.04.2025)

ITCI (intracellulartherapies.com): rincian analitis lan laporan miturut indikator

Ringkesan indikator lan parameter pambiji Intra-Cellular Therapies (ITCI):

Kutipan saham Intra-Cellular Therapies, Inc.|ITCI - Rega prakiraan analis|Kapitalisasi pasar Intra-Cellular Therapies, Inc.

Analisis fundamental perusahaan:ITCI (Intra-Cellular)

Sampel barang Intra-Cellular Therapies Inc.

The market capitalization of Intra-Cellular Therapies (ITCI) reflects the aggregate value of all shares, assessing the potential of its molecular platform in psychiatry. This metric is calculated as the product of the current share price and the total number of outstanding securities. By analyzing the company's market capitalization, an investor can discern the market consensus regarding the commercial success of Caplyta. This chart's price action smooths out short-term speculation, revealing a sustainable valuation trend. Avoid buying at local peaks to prevent capital from being locked up.

Pesaing wigati

Biogen - Biji pasar|Nilai pasar NBIX (Neurocrine)|Regencell - Kapitalisasi pasar|Axsome Corp (AXSM) - Biji pasar|ACAD: Kapitalisasi pasar|XENE - Kapitalisasi pasar|Nilai pasar Viking Therapeutics, Inc.|Kapitalisasi pasar SUPN (Supernus Pharmaceuticals, Inc.)|Kapitalisasi pasar CPRX|DNLI - Nilai pasar|Harmony Biosciences - Biji pasar|Kapitalisasi pasar biohavenpharma.com BHVN|AMLX - Nilai pasar|Nilai pasar TRVI (Trevi Therapeutics Inc)|Praxis Medicines (PRAX) - Nilai pasar|Nilai pasar Anavex Life Sciences Corp (AVXL)|CBLL (CeriBell, Inc.) - Kapitalisasi pasar|Prothena Corp (PRTA) - Kapitalisasi pasar|Nilai pasar Alector, Inc. (ALEC)|Annexon Biosciences - Kapitalisasi pasar|Omeros - Biji pasar|Nilai pasar NGNE (Neurogene Therapeutics)|ACIU - Nilai pasar|Nilai pasar VYGR (voyagertherapeutics.com)|NMRA: Kapitalisasi pasar|Scilex Holding (SCLX) - Kapitalisasi pasar|Biji pasar TVGN|ACOG - Kapitalisasi pasar|Kapitalisasi pasar CGTX|Biji pasar inhibikase.com IKT|Kapitalisasi pasar SAVA (Cassava Sciences)|Assertio Holdings (ASRT) - Nilai pasar|COYA - Nilai pasar|VTGN: Nilai pasar|ovidrx.com (OVID) - Nilai pasar|ABOS (acumenpharm.com) - Nilai pasar|Biji pasar CRVO|Kapitalisasi pasar Alterity Therapeutics Ltd|Nilai pasar Clene Inc. (CLNN)|Nilai pasar PEPG (pepgen.com)|Kapitalisasi pasar JUNS (Jupiter Neurosciences)|Kapitalisasi pasar relmada.com RLMD|ANVS - Nilai pasar|Nilai pasar GRCE (Grace Therapeutics, Inc.)|AIFF (Firefly Neuroscience Inc) - Biji pasar|Klotho Neurosciences - Nilai pasar|Biji pasar NRSN|RVPH (revivapharma.com) - Nilai pasar|Kapitalisasi pasar MTVA|NRXS (NeurAxis Inc.) - Nilai pasar|Kapitalisasi pasar HSDT (Helius Medical Technologies)|Passage Bio Inc. (PASG) - Nilai pasar|NEUP - Nilai pasar|Nilai pasar NERV (minervaneurosciences.com)|ATHA: Kapitalisasi pasar|Addex Therapeutics Ltd. (ADXN) - Kapitalisasi pasar|Nilai pasar Alzamend Neuro Inc.|Cyclerion - Biji pasar|Kapitalisasi pasar PTIX|Kapitalisasi pasar pasitheaclinics.com|Kapitalisasi pasar CRGT (Cortigent)|Avenue Therapeutics Inc. (ATXI) - Nilai pasar|BCLI - Nilai pasar|Kapitalisasi pasar Cara Therapeutics Inc CARA|CHRO: Kapitalisasi pasar|ELYM - Kapitalisasi pasar|Biji pasar LBPH|MRNS (Marinus Pharmaceuticals Inc) - Nilai pasar|Kapitalisasi pasar NKGN|Biji pasar NeuroBo Pharma NRBO|Kapitalisasi pasar SAGE (Sage Therapeutics, Inc.)|Kapitalisasi pasar synaptogen.com (SNPX)|TRVN - Nilai pasar|VIGL (Vigil Neuroscience) - Kapitalisasi pasar|WENA: Kapitalisasi pasar|Nilai pasar Cerevel Corp (CERE)